PepTalk 2017
PepTalk 2017

CONFERENCE SERIES: Bioprocess & Manufacturing

Recorded at: PepTalk: The Protein Science Week

Digital Course: Transient Protein Production In Mammalian Cells: A Short Story

Order DVDTransient Protein Production DVD Cover About this Product: 

This digital short course will introduce the fundamental concepts needed to establish transient protein production in mammalian cells.  This will allow for the rapid generation of milligram to gram quantities of recombinant proteins for therapeutic, functional, and structural studies.  The course will combine instruction and case studies in an interactive environment.

  • A brief overview of protein expression systems
  • An in-depth introduction to mammalian transient expression systems
  • Examination of the key elements necessary for the establishment of a mammalian transient production system
  • Scalable transient protein production
  • Optimizing the transient protein production process



About this Product:
4 Presentations
112 Slides
Over 156 Minutes
Individual: $345
Site License: $1380

Agenda At A Glance: 

Protein Expression Systems Overview 
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, SAIC-Frederick, Inc. 

  • Advantages/Disadvantages of available systems
  • Mammalian expression options

Fundamental Elements of Transient Protein Production
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, SAIC-Frederick, Inc. 

  • Expression Vectors

Dominic EspositoBiography: Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at SAIC-Frederick, Inc.  The 26 employees in the PEL generate proteins of interest to investigators at the National Cancer Institute and other NIH facilities, and invent and develop new technologies for protein expression and production.  Prior to his role as director, Dr. Esposito led the Clone Optimization Group in the PEL for 9 years and was responsible for the generation of over 15,000 expression clones, 400 new expression vectors, and several technological innovations in protein expression. Dr. Esposito received his B.A. in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system. 

Implementing Transient Protein Production
Richard Altman, M.S., Research Scientist, Alexion Pharmaceuticals 

  • What is your goal/objective for transient protein expression?
  • What equipment and space is required?
  • Case Study

Richard AltmanBiography: Mr. Altman has over twenty three years of experience working in the pharmaceutical industry.  For the past two years, he has worked in the Molecular Sciences group at Alexion Pharmaceuticals developing antibody and non-antibody biologics.  Prior to Alexion, he worked for several pharmaceutical companies on the cloning, expression, purification, and characterization of recombinant proteins. This work supported both high throughput screening and protein therapeutic efforts. In addition, he has been involved in the generation of transgenic animal models and their characterization.  Mr. Altman received his M.S. degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry. 

Fundamental Elements of Transient Protein Production
Henry C. Chiou, Ph.D., Senior Manager, Molecular Biology, Life Technologies Corporation 

  • Cell lines
  • Cell culture
  • Transfection reagents and protocols

Ongoing Advances in Transient Protein Production
Henry C. Chiou, Ph.D., Senior Manager, Molecular Biology, Life Technologies Corporation 

Henry ChiouBiography: Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past 9 years he has worked as a principal scientist and now in product development and portfolio management for Life Technologies. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.


About the Conference: 

PepTalk 2012 continues the tradition of strong scientific programming centered around protein-based therapeutics.  The four distinct protein pipelines focused on formulation, purification, biotherapeutics and expression range from applying protein discovery research, to developing downstream protein products that ultimately lead to clinical applications.  This focused design enables you create your own agenda by moving between the tracks and choosing the sessions that best fit your research and networking needs.  Additional networking opportunities will be available through BuzZ Session discussion groups, short courses and panel discussions.